The high prevalence of LATE among individuals with AD – estimated at up to 50% of advanced AD (Braak stage V–VI) in community‐based autopsy cohorts13 – limits attribution of atrophy and clinical symptoms solely to AD pathology, given that standard biomarkers capture amyloid and tau but not TDP‐43 pathology. Here, MAPT is linked to Atrophy.